BPC 157 Capsules Vios Compounding The Wolverine Drug Ortho Rhode Island BPC 157 Banned: Key Facts on the Latest FDA Decision Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA to Review 7 Peptides for Compounding List in July 2026: BPC 157, Semax, Epitalon, and More HealingMaps